Real-Time Update: Becton Dickinson & Co (BDX) Stock Navigates the Market with Up-to-Date Data

The stock of Becton Dickinson & Co (BDX) has seen a -3.82% decrease in the past week, with a -7.23% drop in the past month, and a -5.49% decrease in the past quarter. The volatility ratio for the week is 1.65%, and the volatility levels for the past 30 days are at 2.02% for BDX. The simple moving average for the last 20 days is -4.30% for BDX stock, with a simple moving average of -5.78% for the last 200 days.

Is It Worth Investing in Becton Dickinson & Co (NYSE: BDX) Right Now?

Becton Dickinson & Co (NYSE: BDX) has a price-to-earnings ratio that is above its average at 37.43x. The stock has a 36-month beta value of 0.43. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for BDX is 288.61M, and at present, short sellers hold a 0.71% of that float. On November 21, 2024, the average trading volume of BDX was 1.32M shares.

BDX) stock’s latest price update

The stock price of Becton Dickinson & Co (NYSE: BDX) has plunged by -0.11 when compared to previous closing price of 222.64, but the company has seen a -3.82% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-20 that BROWNSVILLE, Texas , Nov. 20, 2024 /PRNewswire/ — A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities has officially launched in Texas. HPV is the cause of virtually all cervical cancers.

Analysts’ Opinion of BDX

Many brokerage firms have already submitted their reports for BDX stocks, with Citigroup repeating the rating for BDX by listing it as a “Buy.” The predicted price for BDX in the upcoming period, according to Citigroup is $275 based on the research report published on October 01, 2024 of the current year 2024.

Goldman, on the other hand, stated in their research note that they expect to see BDX reach a price target of $274. The rating they have provided for BDX stocks is “Buy” according to the report published on May 30th, 2024.

Raymond James gave a rating of “Outperform” to BDX, setting the target price at $305 in the report published on July 24th of the previous year.

BDX Trading at -5.59% from the 50-Day Moving Average

After a stumble in the market that brought BDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.00% of loss for the given period.

Volatility was left at 2.02%, however, over the last 30 days, the volatility rate increased by 1.65%, as shares sank -7.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.84% lower at present.

During the last 5 trading sessions, BDX fell by -3.82%, which changed the moving average for the period of 200-days by -6.83% in comparison to the 20-day moving average, which settled at $232.38. In addition, Becton Dickinson & Co saw -8.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BDX starting from BURZIK CATHERINE M, who proposed sale 400 shares at the price of $235.78 back on Sep 16 ’24. After this action, BURZIK CATHERINE M now owns shares of Becton Dickinson & Co, valued at $94,312 using the latest closing price.

Spoerel Thomas J, the SVP,Controller&Chief Acct Off of Becton Dickinson & Co, sale 300 shares at $239.31 during a trade that took place back on Jun 10 ’24, which means that Spoerel Thomas J is holding 1,976 shares at $71,793 based on the most recent closing price.

Stock Fundamentals for BDX

Current profitability levels for the company are sitting at:

  • 0.13 for the present operating margin
  • 0.45 for the gross margin

The net margin for Becton Dickinson & Co stands at 0.09. The total capital return value is set at 0.05. Equity return is now at value 6.68, with 3.14 for asset returns.

Based on Becton Dickinson & Co (BDX), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is 5.0.

Currently, EBITDA for the company is 2.42 billion with net debt to EBITDA at 4.04. When we switch over and look at the enterprise to sales, we see a ratio of 4.03. The receivables turnover for the company is 6.65for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.

Conclusion

To sum up, Becton Dickinson & Co (BDX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts